Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide for high-output enterocutaneous fistula or enterostomy
NL-OMON44776Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lanreotide in enterocutaneous fistula (ECF) and intestinal stoma complication (2 arms), sponsored by Amsterdam University Medical Center. Started Mar 2014; status: active, not recruiting.
02
Drugs
lanreotide
03
Conditions
enterocutaneous fistula (ECF)intestinal stoma complication
Beyond the preview
Go deeper on NL-OMON44776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44776.